An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study

@inproceedings{Lazzaro2013AnIC,
  title={An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study},
  author={Carlo Lazzaro and Roberto Bordonaro and Francesco Cognetti and Alessandra Fabi and Sabino De Placido and Grazia Arpino and Paolo Marchetti and Andrea Botticelli and Paolo Pronzato and Elisa Martelli},
  booktitle={ClinicoEconomics and outcomes research : CEOR},
  year={2013}
}
PURPOSE Paclitaxel albumin (nab-paclitaxel) is a nanoparticle albumin-bound paclitaxel formulation aimed at increasing therapeutic index in metastatic breast cancer. When compared to conventional paclitaxel, nab-paclitaxel has a reported longer time to progression, higher response, lower incidence of neutropenia, no need for premedication, shorter time of administration, and in pretreated metastatic breast cancer patients, extended overall survival. This study investigates the cost… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Neoadjuvant nab-paclitaxel in the treatment of breast cancer

Breast Cancer Research and Treatment • 2016
View 8 Excerpts
Highly Influenced

Structural Uncertainty of Markov Models for Advanced Breast Cancer: A Simulation Study of Lapatinib.

Medical decision making : an international journal of the Society for Medical Decision Making • 2016

Understanding the economic impact of intravascular ultrasound (IVUS)

The European Journal of Health Economics • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2005
View 9 Excerpts
Highly Influenced

A UK costeffectiveness analysis of paclitaxel albumin compared to solvent-based paclitaxel monotherapy and docetaxel monotherapy for pretreated metastatic breast cancer (MBC)

E McLeod, Y Samyshkin, A Lloyd, F Prunieras, P. Canney
Proceedings of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual European Congress; November • 2010
View 3 Excerpts
Highly Influenced

Sampling: Design and Analysis, 2nd ed

SL Lohr
2010
View 7 Excerpts
Highly Influenced

Methods for the Economic Evaluation of Health Care Programmes, 3rd ed

MF Drummond, MJ Schulper, GW Torrance, BJ O’Brien, GL. Stoddart
2005
View 8 Excerpts
Highly Influenced

Cost-effectiveness in Health and Medicine

MR Gold, JE Siegel, LB Russel, MC Weinstein, editors
1996
View 7 Excerpts
Highly Influenced

Economic Evaluation in Clinical Trials, 2nd Edition.

Australian and New Zealand journal of public health • 2015
View 2 Excerpts

Quotazioni in Euro [homepage on the Internet

Available from: http://cambi.bancaditalia. it/cambi/cambi.do?lingua=it&to=cambiGForm. Accessed October • 2011

homepage on the Internet]. Cancer incidence and mortality worldwide: IARC CancerBase

J Ferlay, HR Shin, +3 authors DM Parkin
No 10. Lyon: International Agency for Research on Cancer; • 2010
View 1 Excerpt

Consumo di risorse e costi nei pazienti con carcinoma alla mammella metastatizzato HER2+

S Gerzeli, G. Aguzzi
Italian Journal of Public Health • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…